Harish Chowdary Gorrepati/LinkedIn
Sep 1, 2026, 15:09
Harish Chowdary Gorrepati: The HALT Paradox After TAV
Harish Chowdary Gorrepati, Interventional Cardiologist at Sri Venkateswara Institute of Medical Sciences (SVIMS), Tirupati, Fellow at Heart Center UMC, shared a post on LinkedIn:
“NOTION-4 Trial | TAVR and Antithrombotic Therapy.
Short-term DOAC after TAVR significantly reduced HALT at 3 months (31.8 percent – 12.1 percent), but this benefit was not sustained at 12 months (32.2 percent versus 28.3 percent; P=0.54).
Importantly, bleeding/clinical events were numerically higher with the DOAC strategy.
Key message: Reducing leaflet thrombosis on CT does not necessarily translate into better clinical outcomes.
SAPT remains the preferred strategy for patients without another indication for oral anticoagulation.”
Stay updated with Hemostasis Today.
-
Sep 1, 2026, 18:13Ramsha Batool: Chemotherapy-Induced Anemia Impacts Quality of Life in Breast Cancer
-
Sep 1, 2026, 18:09Natalya Shynhera: Using Anemia to Teach Medical English in Real Clinical Practice
-
Sep 1, 2026, 18:06Wei Du: New Therapeutic Potential for PARP Inhibitors in MLL-Rearranged Leukemia
-
Sep 1, 2026, 18:03Tobias Tichelbäcker: PRAGUE-26 Shows Catheter Lysis Beats Anticoagulation Without Ultrasound
-
Sep 1, 2026, 18:00Baptiste Thibault: My First Publication as First Author on Ionized Calcium Monitoring Before Citrate-CRRT
-
Sep 1, 2026, 17:51Nadezhda Vasilyeva: Shifting the Boundaries of Acute Ischemic Stroke Management
-
Sep 1, 2026, 17:49Malik Ghannam: Recent Venous Thrombosis Risk Factors May Help Explain Cryptogenic Stroke in Young Adults
-
Sep 1, 2026, 17:42Rishabh Jain: Renal Artery FMD Is Managed With Balloon Angioplasty Alone
-
Sep 1, 2026, 17:42Caitlin R: The Brain’s Need to Find Patterns